Botulinum Toxin A in Frequent and Chronic Tension-type Headache
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Chronic tension-type headache (CTTH) is an underestimated disabling condition that affects a
large number of patients. The treatment options for both episodic tension-type headaches, but
especially CTTH are few. Poor long-term effects of existing treatment for CTTH (Sarotex,
SSRIs, physiotherapy) are reported. Patients with CTTH also have a high risk of developing
drug overdose headache (MOH). Non-drug treatments with physiotherapy/ alternative medicine
also show poor long-term effects. And literature reviews shoes that there is surprisingly
little research on CTTH. Some small clinical trials report a good effect of treatment with
botulinum toxin A in CTTH, but larger controlled trials are needed to confirm or deny this.
We will study effect of treatment with botulinum toxin A in CTTH in BACT study, and we will
include participants with both frequent and chronic TTH with 10 or more headache days per
month.
If BACT outcomes are positive, it will open a possibillity for a new treatment for TTH
patients.
Phase:
Phase 3
Details
Lead Sponsor:
Central Norway Regional Health Authority Helse Nord-Trøndelag HF
Collaborators:
Norwegian University of Science and Technology Sandvika Nevrosenter
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A Pharmaceutical Solutions